Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesARCA Biopharma Inc

ARCA Biopharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2024-09-30T06:06:49.942053Z
Market Cap
51.50M

Momentum Score

…

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.56
Low
4.49
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-15.87%
Net Debt
-37.15M
ROCE
-28.77%
Diluted EPS TTM
-0.42

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -9.93M -19.32M -9.75M -5.65M -7.96M
Net income -9.26M -19.23M -9.74M -5.48M -7.93M
Selling general administrative 5.85M 5.50M 4.77M 3.98M 3.88M
Gross profit - - - - 0.00M
Reconciled depreciation 0.11M 0.09M 0.09M 0.09M 0.02M
Ebit -10.71M -19.34M -9.77M -5.81M -7.96M
Ebitda -10.60M -19.32M -9.74M -5.55M -7.93M
Depreciation and amortization 0.11M 0.01M 0.03M 0.26M 0.02M
Non operating income net other - - 0.03M 0.17M 0.16M
Operating income -10.60M -19.34M -9.77M -5.81M -8.12M
Other operating expenses 10.60M 19.34M 9.77M 5.81M 8.12M
Interest expense 0.68M 0.01M 0.01M 0.01M 0.01M
Tax provision - 0.00M -0.01M -0.17M -0.03M
Interest income 0.68M 0.01M 0.03M 0.17M 0.16M
Net interest income 0.68M 0.01M 0.02M 0.17M 0.15M
Income tax expense -0.67M -0.09M -0.01M -0.17M -0.03M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 10.60M 19.34M 9.77M 5.81M 8.12M
Cost of revenue - - - - 0.00M
Total other income expense net 0.67M 0.01M 0.02M 0.17M 0.15M
Net income from continuing ops -9.93M -19.32M -9.74M -5.48M -7.93M
Net income applicable to common shares -9.93M -19.32M -9.74M -5.48M -7.93M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 37.86M 43.09M 54.92M 50.43M 8.54M
Other current assets 0.16M 0.25M 1.06M 0.90M 0.12M
Total liab 0.84M 1.41M 3.88M 3.91M 0.93M
Total stockholder equity 37.02M 41.67M 51.04M 46.52M 7.61M
Other current liab 0.56M 0.80M 2.38M 1.73M 0.51M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -188.74M -183.40M -173.48M -154.15M -144.42M
Other assets 0.00M 0.02M 0.02M 0.44M 0.02M
Cash 37.43M 42.45M 53.36M 49.07M 8.36M
Total current liabilities 0.64M 1.13M 3.50M 3.50M 0.93M
Current deferred revenue -0.36M - - - -
Net debt -37.15M -42.16M -52.98M -48.66M -8.36M
Short term debt 0.08M - - 3.66M -
Short long term debt total 0.28M 0.28M 0.38M 0.41M -
Other stockholder equity 225.75M 225.06M 224.50M 200.66M 152.02M
Property plant equipment - 0.37M 0.48M 0.45M 0.01M
Total current assets 37.59M 42.70M 54.42M 49.97M 8.48M
Net tangible assets - 41.67M 51.04M 46.52M 7.61M
Accounts payable 0.36M 0.33M 1.12M 1.77M 0.42M
Accumulated other comprehensive income - - - - -0.37M
Common stock total equity - - - 0.01M 0.00M
Retained earnings total equity - - - -154.15M -144.42M
Non currrent assets other 0.01M 0.02M 0.02M 0.01M 0.02M
Non current assets total 0.27M 0.39M 0.50M 0.46M 0.06M
Capital lease obligations 0.20M 0.28M 0.38M 0.41M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.00M -0.04M -0.02M -0.00M 3.05M
Change to liabilities -0.78M -0.41M 1.10M 0.04M -1.30M
Total cashflows from investing activities -0.00M -0.04M -0.02M -0.00M 3.05M
Net borrowings - - -0.41M -0.35M -0.31M
Total cash from financing activities 0.00M 23.09M 48.45M 6.56M 3.10M
Change to operating activities -0.88M 0.38M 0.78M 0.25M -0.22M
Net income -9.93M -19.32M -9.74M -5.48M -7.93M
Change in cash -10.91M 4.29M 40.71M 1.75M -2.09M
Begin period cash flow 53.36M 49.07M 8.36M 6.61M 8.70M
End period cash flow 42.45M 53.36M 49.07M 8.36M 6.61M
Total cash from operating activities -10.91M -18.76M -7.72M -4.80M -8.24M
Issuance of capital stock 0.00M 24.07M 50.89M 7.28M 3.53M
Depreciation 0.11M 0.09M 0.09M 0.09M 0.02M
Other cashflows from investing activities - - - - 3.05M
Sale purchase of stock - - 48.86M 6.91M 3.42M
Other cashflows from financing activities -0.00M -0.98M -2.44M -0.72M -0.43M
Change to netincome 0.56M 0.50M 0.04M 0.15M 0.27M
Capital expenditures 0.00M 0.04M 0.02M 0.00M 0.00M
Cash flows other operating - - -0.28M 0.47M 0.69M
Cash and cash equivalents changes - - 40.71M 1.75M -2.09M
Change in working capital -1.66M -0.03M 1.88M 0.44M -0.61M
Stock based compensation 0.56M 0.50M 0.04M 0.15M 0.27M
Other non cash items 0.01M 19.35M -37.04M -1.13M 0.00M
Free cash flow -10.91M -18.80M -7.74M -4.80M -8.25M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

ARCA Biopharma Inc

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

10170 Church Ranch Way, Westminster, CO, United States, 80021

720 940 2200

https://www.arcabio.com

4

Name Title Year Born
Dr. Michael R. Bristow M.D., Ph.D. Co-Founder, Pres, CEO & Director 1945
Mr. Thomas A. Keuer Chief Operating Officer 1959
Mr. Christopher D. Ozeroff Sr. VP, Gen. Counsel & Sec. 1959
Mr. C. Jeffrey Dekker CPA Chief Financial Officer 1965
Dr. Michael R. Bristow M.D., Ph.D. Co-Founder, President, CEO & Director 1945
Mr. C. Jeffrey Dekker CPA CFO, Treasurer & Company Secretary 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…